BIONTECH SE (BNTX): Price and Financial Metrics
BNTX Stock Summary
- BioNTech SE's stock had its IPO on October 10, 2019, making it an older stock than merely 1.22% of US equities in our set.
- BNTX's price/sales ratio is 178.84; that's higher than the P/S ratio of 97.6% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, BioNTech SE is reporting a growth rate of 292.66%; that's higher than 94.82% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to BioNTech SE are ENTA, MORF, ANAB, CARA, and RCUS.
- BNTX's SEC filings can be seen here. And to visit BioNTech SE's official web site, go to www.biontech.de.
BNTX Stock Price Chart Interactive Chart >
BNTX Price/Volume Stats
|Current price||$96.20||52-week high||$131.00|
|Prev. close||$95.15||52-week low||$28.00|
|Day high||$96.84||Avg. volume||2,170,305|
|50-day MA||$105.83||Dividend yield||N/A|
|200-day MA||$85.23||Market Cap||23.16B|
BIONTECH SE (BNTX) Company Bio
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.
BNTX Latest News Stream
|Loading, please wait...|
BNTX Latest Social Stream
View Full BNTX Social Stream
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
Betsy Price, Fort Worth Mayor, joins Yahoo Finance’s Kristin Myers to discuss Texas lifting its mask mandates and reopening businesses.
Yahoo Finance’s Julie Hyman, Brian Sozzi, and Myles Uldand discuss expectations in the health care sector with Oppenheimer Analyst Hartaj Singh.
Dr. Heather Yeo, SurvivorNet Medical Advisor & Associate Professor of Surgery and Associate Professor of Population Health Sciences at New York Presbyterian Weill Cornell Medicine, joins Yahoo Finance’s Kristin Myers to discuss the latest coronavirus updates.
Novavax said in January its coronavirus vaccine was 89.3% effective in a Phase 3 test. It's also effective against variants. It's now seeking authorization. Is NVAX stock a buy?
The European Union drug regulator does not see enough evidence yet to recommend changes to the dosage regime for COVID-19 vaccines, despite pressure from EU states after positive data on the level of protection of a single shot. EU nations' vaccination plans are lagging behind the United States and former EU member Britain, a delay that has prompted some countries to push for new approaches, including on the administration of vaccines. For the Pfizer-BioNTech vaccine, London recommends the booster should be given after 12 weeks, whereas the guidance from the European Medicines Agency (EMA) follows the companies' recommendations of a second dose after three weeks.
BNTX Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!